Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis

Gut

Volumn 40, Issue 6, 1997, Pages 775-781

  Marshall, J K ^a   Irvine, E J ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Corticosteroids; Enema; Suppository; Therapy; Topical administration; Ulcerative colitis

Indexed keywords

BUDESONIDE; CORTICOSTEROID; ENEMA; MESALAZINE;

ARTICLE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ENDOSCOPY; HUMAN; MEDICAL ETHICS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SUPPOSITORY; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0030848283     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.6.775     Document Type: Article

References (67)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: preliminary report on a therapeutic trial. BMJ 1954; 2: 375-8.
2. Truelove SC. Treatment of ulcerative colitis with local hydrocortisone. BMJ 1956; 2: 1267-72.
3. Mulder CJJ, Tytgat GNJ. Topical corticosteroids in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 125-30.
4. Chapman NJ, Brown ML, Phillips SF, Tremaine WJ, Schroeder KW, Dewanjee MK, et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992; 67: 245-8.
5. Tiel-van Buul MMC, Mulder CJJ, van Royen EA, Wiltink EHH, Tytgat GNJ. Retrograde spread of mesalazine (5-aminosalicylic acid)-containing enema in patients with ulcerative colitis. Clin Pharmacokinet 1991; 20: 247-51.
6. Jay M, Digenis GA, Foster TS, Antonow DR. Retrograde spreading of hydrocortisone enema in inflammatory bowel disease. Dig Dis Sci 1986; 31: 139-44.
7. Campieri M, Lanfranchi GA, Brignola C, Bazzocchi G, Gionchetti P, Minguzzi MR, et al. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum 1986; 29: 108-10.
8. Kruis W, Bull U, Eisenburg J, Paumgartner G. Retrograde colonic spread of sulphasalazine enemas. Scand J Gastroenterol 1982; 17: 933-8.
9. Nymann-Pantelidis M, Nilsson A, Wagner ZG, Borga O. Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 617-22.
10. Swarbrick ET, Loose H, Lennard-Jones JE. Enema volume as an important factor in successful topical corticosteroid treatment of colitis. Proc Royal Soc Med 1974; 67: 753-4.
11. Van Bodegraven AA, Boer RO, Lourens J, Tuynman HARE, Sindram JW. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996; 10: 327-32.
12. Farthing MJG, Rutland MD, Clark ML. Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis. BMJ 1979; 2: 822-4.
13. Hay DJ. Spreading characteristics of proprietary rectal steroid preparations. In: Wilson CG, Hardy JG, eds. Radionuclide imaging in drug research. London: Croom Helm, 1982: 71-80.
14. Wood E, Wilson CG, Hardy JG. The spreading of foam and solution enemas. Int J Pharmaceut 1985; 25: 191-7.
15. Campieri M, Corbelli C, Gionchetti P, Brignola C, Belluzzi A, Di Febo G, et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enemas in patients with ulcerative colitis. Dig Dis Sci 1992; 37: 1890-7.
16. Wilding IR, Kenyon CJ, Chauhan S, Hooper G, Marshall S, McCracken JS, et al. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 161-6.
17. Williams CN, Haher G, Aquino JA. Double-blind, placebocontrolled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99m-Tc-labelled 5-ASA suppositories. Dig Dis Sci 1987; 32: 71S-5S.
18. Jay M, Beihn RM, Digenis GA, Deland FH, Caldwell L, Mlodozeniec AR. Disposition of radiolabelled suppositories in humans. J Pharm Pharmacol 1985; 37: 266-8.
19. Powell Tuck J, Lennard-Jones JE, May CS, Wilson CG, Paterson JW. Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis. BMJ 1976; 1: 193-5.
20. Lee DAH, Taylor GM, James VHT, Walker G. Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema. Gut 1979; 20: 349-55.
21. Farmer RG, Schumacher OP. Treatment of ulcerative colitis with hydrocortisone enemas: relationship of hydrocortisone absorption, adrenal suppression, and clinical response. Dis Colon Rectum 1970; 13: 355-61.
22. Luman W, Gray RS, Pendek R, Palmer KR. Prednisolone metasulphobenzoate foam retention enemas suppress the hypothalamo-pituitary-adrenal axis. Aliment Pharmacol Ther 1994; 8: 255-8.
23. Cann PA, Holdsworth CD. Systemic absorption from hydrocortisone foam enema in ulcerative colitis. Lancet 1987; i: 922-3.
24. Bianchi Porro G, Prantera C, Campieri M, Petrillo M, Campanini MC, Gionchetti P, et al. Comparative trial of methylprednisolone and budesonide enemas in the treatment of active distal ulcerative colitis. Eur J Gastroenterol Hepatol 1994; 6: 125-30.
25. Danielsson A, Hellers G, Lyrenas E, Lofberg R, Nilsson A, Olsson O, et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987; 22: 987-92.
26. Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. Scand J Gastroenterol 1991; 26: 1225-30.
27. Spencer CM, McTavish D. Budesonide: a review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50: 854-72.
28. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-14.
29. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 293-300.
30. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Wonsiewica MJ, McCurdy P, eds. Goodman and Gilman's The pharmacological basis of therapeutics. New York: McGraw Hill, 1996: 466.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-80.
32. Bracken MB. Statistical methods for analysis of effects of treatment in overviews of randomized trials. In: Sinclair JC, Bracken MB, eds. Effective care of the newborn infant. Oxford: Oxford University Press, 1992: 15-6.
33. Breslow NE, Day NE (eds). Statistical methods in cancer research. Lyon: International Agency for Research on Cancer, 1980: 136-46.
34. Lennard-Jones JE, Baron JH, Connell AM, Avery Jones F. A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Gut 1962; 3: 207-10.
35. Watkinson G. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium: a controlled trial employing restricted sequential analysis. BMJ 1958; 2: 1077-82.
36. Danielsson A, Lofberg R, Persson T, Salde L, Schioler R, Suhr O, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992; 27: 9-12.
37. Hanauer S, Robinson M. Dose ranging study of budesonide enemas in active distal ulcerative colitis [abstract]. Gastroenterology 1995; 108: A832.
38. Hamilton I, Pinder IF, Dickinson RJ, Ruddel WSJ, Dixon MF, Axon ATR. A comparison of prednisolone enemas with low-dose oral prednisolone in the treatment of acute distal ulcerative colitis. Dis Colon Rectum 1984; 27: 701-2.
39. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery Jones F. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960; 1: 217-22.
40. Bianchi Porro G, Ardizzone S, Petrillo M, Fasoli A, Molteni P, Imbesi V. Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized double blind study. Am J Gastroenterol 1995; 90: 736-9.
41. Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Sarti F, Franzin G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; ii: 270-1.
42. Danish 5-ASA Study Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. Dig Dis Sci 1987; 32: 598-602.
43. Farup PG, Hovde O, Halvorsen FA, Raknerud N, Brodin U. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. Scand J Gastroenterol 1995; 30: 164-70.
44. Friedman LS, Richter JM, Kirkham SE, DeMonaco HJ, May RJ. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized controlled trial. Am J Gastroenterol 1986; 81: 412-8.
45. Lee FI, Jewell DP, Mani V, Keighley MRB, Kingston RD, Record CO, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996; 38: 229-33.
46. Mulder CJJ, Enden E, Van der Heide H, Houthoff HJ, Wiersinga W, Wiltink EHH, et al. Comparison of 5-aminosalicylic acid (3g) and prednisolone phosphate sodium (enemas (30mg) in the treatment of distal ulcerative colitis: a prospective, randomized, double-blind trial. Scand J Gastroenterol 1988; 23: 1005-8.
47. O'Donnell LJD, Arvind AS, Cameron D, Talbot IC, Jewell DP, Lennard-Jones JE, et al. Double blind, controlled trials of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. Gut 1992, 33: 947-9.
48. Sharma MP, Duphare HV, Dasarathy S. A prospective randomized double blind trial comparing prednisolone and 4-aminosalicylic acid enemas in acute distal ulcerative colitis. J Gastroenterol Hepatol 1992; 7: 173-7.
49. Lofberg R, Ostergaard Thomsen O, Langholz E, Schioler R, Danielsson A, Suhr O, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 623-9.
50. Tarpila S, Turunen U, Seppala K, Aukee S, Pikkarainen P, Elomaa I, et al. Budesonide enema in active haemorrhagic proctitis: a controlled trial against hydrocortisone foam enema. Aliment Pharmacol Ther 1994; 8: 591-5.
51. Lamers C, Meijer J, Engels L, Bos L, Van Hogezand R, Driesson W, et al. Comparative study of the topically acting glucocorticoid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis [abstract]. Gastroenterology 1991; 100: A223.
52. Lemann M, Galian A, Rutgeerts P, van Heuverzwijn R, Cortot A, Viteau JM, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 557-62.
53. Cobden I, Al-Mardini H, Zaitoun A, Record CO. Is topical therapy necessary in acute distal ulcerative colitis? Double-blind comparison of high-dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis. Aliment Pharmacol Ther 1991; 5: 513-22.
54. Grace RH, Gent AE, Hellier MD. Comparative trial of sodium cromoglycate enemas with prednisolone enemas in the treatment of ulcerative colitis. Gut 1987; 28: 88-92.
55. Halpern Z, Sold O, Baratz M, Konikoff F, Halak A, Gilat T. A controlled trial of beclomethasone versus betamethasone enemas in distal ulcerative colitis. J Clin Gastroenterol 1991; 13: 38-11.
56. Hanauer SB, Kirsner JB, Barrett WE. The treatment of left-sided ulcerative colitis with tixocortol pivalate [abstract]. Gastroenterology 1986; 90: A1449.
57. Lennard-Jones JE. Betamethasone 17-valerate and prednisolone 21-phosphate retention enemas in proctocolitis. BMJ 1971; 3: 84-6.
58. Mulder CJJ, Enden E, Van der Heide H, Houthoff HJ, Wiersinga W, Wiltink EHH, et al. Comparison of beclomethasone diproprionate (2 and 3mg) and prednisolone sodium phosphate enemas (30mg) in the treatment of ulcerative proctitis: an adrenocortical approach. Neth J Med 1989; 35: 18-24.
59. Mulder CJ, Fockens P, Van der Heide H, Tytgat GNJ. A controlled randomized trial of beclomethasone dipropionate (3mg) versus 5-ASA (1g) versus the combination of both (3mg/1g) as retention enemas in active distal ulcerative colitis [abstract]. Gastroenterology 1994; 106: A739.
60. Riley SA, Gupta I, Mani V. A comparison of sucralfate and prednisolone enemas in the treatment of active distal ulcerative colitis. Scand J Gastroenterol 1989; 24: 1014-8.
61. Ruddell WSJ, Dickinson RJ, Dixon MF, Axon ATR. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparsion of hydrocortisone enemas and rectal hydrocortisone foam. Gut 1980; 21: 885-9.
62. Van der Heide H, Van den Brandt-Gradel, Tytgat GNJ, Enden E, Wiltink EHH, Schipper MEI, et al. Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988; 10: 169-72.
63. Van Outryve M, Huble F, Van Eeghem P, De Vos M. Comparison of ridogrel versus prednisolone, both administered rectally, for the treatment of active ulcerative colitis [abstract]. Gastroenterology 1996; 110: A1035.
64. Ilnycki A, Shanahan F, Anton PA, Cheang M, Bernstein CN. The placebo response in ulcerative colitis [abstract]. Gastroenterology 1996; 110: A929.
65. Meyers S, Janowitz HD. The natural history of ulcerative colitis: an analysis of the placebo response. J Clin Gastroenterol 1989; 11: 33-7.
66. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
67. Irvine EJ. Assessing outcome in randomized clinical trials: inflammatory bowel disease. Can J Gastroenterol 1993; 7: 561-7.